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Background 
 
 
Streptococcus agalactiae, Group B streptococcus or commonly GBS, became known as an 
agent infecting udders of cows and was therefore given the name Streptococcus agalactiae 
contagiosae. The name was later shortened to Streptococcus agalactiae (want of milk) [1]. 
GBS was first described as a cause of human infection in 1938, when three patients with fatal 
puerperal sepsis were described [2]. The bacteria remained unknown to most clinicians until 
the 1970s, when a dramatic increase of GBS septicaemia and meningitis in neonates was 
observed in different parts of the world [3]. GBS became the most prevalent agent of serious 
neonatal infections and was detected in more than 40% of invasive isolates from neonates [4]. 
In the same period, an increasing number of GBS infections was observed in pregnant women 
and non pregnant adults.  
The clinical course of invasive GBS disease in infants is often dramatic, with high 
morbidity, and until the middle of 1980s the case fatality was more than 50%. Research on the 
epidemiology and pathogenesis of GBS was initiated, and preventive actions like antibiotic 
prophylaxis during labour to women at risk of having a child with GBS infection were 
introduced in USA and Europe in the 1990s. Two different strategies to identify women at 
risk were recommended; the risk-factor strategy and the screening strategy. Risk factors are 
prolonged rupture of membranes, premature birth, intrapartum fever, previous GBS infected 
infant or GBS bacteriuria detected during the current pregnancy, and GBS colonisation of the 
pregnant woman. In the USA, screening for GBS colonisation is at present recommended in 
week 35-37. However, rapid molecular methods like real-time PCR might replace the 
traditional culture screening, and make screening possible when the women are in labour.  
Even if intrapartum antibiotics have reduced early onset GBS disease it will not be 
100% effective and antibiotic prophylaxis during labour has no effect on late onset GBS 
disease. Vaccines based on GBS antigens have been developed, and maternal vaccination is 
expected to prevent GBS disease in neonates, but final trials and implementation still lie some 
years ahead. Variations of GBS characteristics have implications for the formulation of GBS 
vaccines. Thus, surveillance of GBS is of importance. 
This study aimed to describe the epidemiology of GBS disease in Norway and 
characterise invasive GBS strains by phenotypic and genotypic methods. The performance of 
a molecular method for detection of GBS in pregnant women during labour, and a possible 
implementation of this or similar methods in intrapartum screening were studied.  
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Group B streptococci 
 
Morphology and identification  
Streptococcus agalactiae (Group B streptococcus; GBS) is the species designation for 
streptococci belonging to the Lancefield group B. GBS are facultative anaerobic gram 
positive cocci and form chains of variable length that grow on a variety of media. Colonies 
are 1-3 mm in diameter and greyish-white in colour when grown on sheep blood agar. The flat 
mucoid colonies are surrounded by a clear zone, caused by lysis of red blood cells in the agar 
medium, induced by bacterial haemolysins (β-haemolysis). Streptococci which generate β-
haemolysis are also called β-haemolytic streptococci. 1-2 percent of the GBS strains are non-
haemolytic [1].  
 
GBS antigens  
GBS has two distinct polysaccharide antigens; the group B specific antigen which is common 
to all strains, and the type specific capsular polysaccharides (CPS) which further divide GBS 
into serotypes. Other important antigens in GBS are the various strain variable or surface-
anchored proteins.  
Definitive identification of GBS requires detection of the group B specific antigen. 
Hyperimmune group B specific antisera or monoclonal antibodies have been developed to 
detect the GBS antigen. Latex agglutination is one of the most widely used methods.   
 
Serotypes 
Almost all clinical isolates of GBS carry a capsular polysaccharide (CPS) and can be 
classified into ten distinct serotypes or CPS types; Ia, Ib and II-IX [5;6]. The type specific 
polysaccharides are repeating units of five to seven monosaccharides (glucose, galactose, 
glucosamine, and N-acetylneuraminic acid, or sialic acid). The primary serologic method used 
for serotype determination was antigen extraction and precipitation reactions with adsorbed 
whole-cell antisera introduced by Lancefield in 1934 [7;8]. The fluorescent antibody test 
(FAT) described by Bevanger et al [9] is an alternative method of serotyping. A Latex 
agglutination test is also developed for serotyping of GBS [10]. Most GBS isolates can be 
classified into serotypes, but 4 to 7% do not react with hyperimmune sera to the characterised 
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capsular polysaccharides and are referred to as nontypeable [11]. Apart from technical 
reasons, nontypeability might be explained if the isolate is a nonencapsulated variant and if 
the isolate produces an uncharacterised polysaccharide for which antibodies not yet are 
available (a new serotype). Nontypeability can also be explained if the isolate has an insertion 
or a mutation in genes that are essential for capsule expression [12-14]. 
Recently, molecular typing of GBS based on detection of serotype-specific gene 
clusters of the capsular region has been developed [15]. In some studies, and also in routine 
characterisation of GBS, such molecular typing has now become more common [15;16]. 
 
Surface proteins 
Most GBS strains express a variety of surface proteins. Many of the surface protein antigens 
induce protective immunity in animal models and are potential vaccine candidates [17]. The 
first surface protein identified in GBS was the c antigen [18]. The c antigen is composed of 
the trypsin resistant α-protein and the trypsin sensitive beta protein [19]. A GBS strain may 
express α c protein, β c protein, or both. The major surface-localised proteins include α c 
protein and β c protein, the R proteins R1, R3 and R4 (the last of these has been shown to be 
identical to Rib) [20;21], and the alpha like proteins Alp2 and Alp3 which may be variants of 
the R1 protein [22]. The epsilon (ε) protein has also been called Alp1. The alpha c protein, 
Rib, Alp2, Alp3 and the epsilon/Alp1 protein are, unlike the β c protein, characterised by 
similarity in primary structure, with up to 100% homology for some of the protein stretches 
[23], and by their generation of ladder-like patterns on Western blots. The patterns are 
probably due to large and identical repeat units which vary in number from strain to strain 
[23-25]. The proteins are encoded by stable mosaic genes, generated by a recombination of 
modules at the same chromosomal locus [26;27]. The bca, ε/alp1, bac, rib, alp2 and alp3 
genes encode α c protein, epsilon/Alp1, β c protein, Rib, Alp2 and Alp3, respectively.  
 
Subtypes 
Subtyping is a more detailed categorisation of GBS, where GBS categories are based on the 
combination of capsular polysaccharide (CPS) and surface proteins, called serovariants. For 
instance, serotype III can be subdivided into the serovariants III/R4 or III/ c-αβ, type Ia into the 
variants Ia/c-α and Ia/c-αβ.  
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Table 1 shows the nomenclature of GBS c and R proteins and the most common 
capsular serotypes associated with the protein. 
 
 
 
  
 
 
Table 1 Nomenclature and some characteristics of GBS c and R proteins  (L.Bevanger, 
personal communication) 
 
Designation Alternate 
designation 
Gene Most common capsular 
serotype associated 
c proteins 
beta   bac Ib 
alpha   bca Ib 
alpha, epsilon variant  Alp1 epsilon/Alp1  Ia 
R proteins 
R1 Alp2* alp2 III 
R1 Alp3*, R28 alp3 V, VIII 
R3   ? V 
R4 Rib rib; r4 III 
R5 BPS sar5 found in strain Compton 
25/60  
* Alp2 and Alp3 are considered variants of classical R1 protein 
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Genome sequence of GBS 
The GBS genome consists of a circular chromosome. The complete genome sequences have 
been obtained for NEM316 [28], 2603V/R [29] and A909 [30] belonging to serotypes III, V 
and Ia respectively. Sequence analyses have revealed the composite organization with a stable 
backbone and 11–14 interspersed islands which are associated with virulence genes. 
Comparison of the genome sequences has defined a core genome of about 1800 genes shared 
by all isolates, accounting for ~80% of any single genome, plus a dispensable genome 
consisting of partially shared and strain-specific genes [30].  
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Epidemiological typing 
Serologic or molecular typing of CPS and surface proteins distinguish between isolates of a 
microbial population, but may be insufficient in detecting virulent clones in a local outbreak 
and are also inadequate for evolutionary studies. Molecular typing methods may identify 
clones or closely related strains recovered from an outbreak, describe the population in an 
area and show the relatedness of isolates from different geographic areas to common 
ancestors. Several methods of molecular typing have been developed; the two most widely 
used methods in epidemiological studies of GBS at present are pulsed-field gel 
electrophoresis (PFGE) and Multilocus sequence typing (MLST).  
 
PFGE                                                                                                                                       
The method may detect genetic variation that accumulates relatively rapid. Random genetic 
events, including point mutations, insertions and deletions of DNA may alter the PFGE 
pattern during an outbreak. With this method, genomic DNA of the bacteria is cut into large 
fragments by using infrequent-cutting restriction enzymes. Unlike small DNA fragments that 
can be resolved by conventional electrophoresis, these large fragments need to be separated in 
special electric fields with a pulsed current. Alternating electric fields run the DNA fragments 
through a gel matrix of agarose and organise the fragments in the gel according to their 
molecular size [31;32]. The PFGE profiles may be analysed by visual assessment of bands. 
Similarity of band patterns of different strains may also be assessed by similarity coefficients 
(Dice, Jaccard), which can be used for construction of dendrograms by methods like 
Unweighted Pair Group Method with Mathematical Averages (UWPMA or UPGMA) (Figure 
1). The dendrogram provides a quantitative assessment of strain similarity [33]. PFGE is a 
frequently used method for studies of outbreaks and local epidemiology of different bacteria 
including GBS, but is considered to be too discriminatory for studies of evolutionary 
relationships in isolates. Another drawback of PFGE is that gel-based analyses are not easily 
comparable from one laboratory to another (low portability) [34-36].  
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Figure1 Image of Pulsed-field gel electrophoresis (PFGE) of type V strains from 18 infants 
with invasive GBS disease in Norway 2006 and 2007 (Figure from Paper II). The dendrogram 
on the left side of the figure was constructed with the unweighted pair-group method with 
arithmetic mean (UPGMA) using Bionumerics (version 5.10, Applied Maths, Sint-Martens-
Latem, Belgium). Cluster analysis of PFGE fragment patterns was done using the Dice 
coefficients.   
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MLST                  
Data from MLST can be used to investigate evolutionary relationships among bacteria. While 
PFGE is a gel-based analysis and dependent on visual interpretation, MLST is a more 
unambiguous genotyping method and sequence data are transferable between laboratories 
[31]. The method provides the sequences of 450-500 base pairs from fragments of seven 
“housekeeping genes” encoding central metabolic enzymes in the organism [37;38]. For each 
housekeeping gene, the nucleotide sequences may vary. The variants of the genes are assigned 
as alleles, and the combination of alleles at each of the seven loci represent an allelic profile 
which unambiguously defines the sequence type (ST) of each isolate. In MLST the number of 
nucleotide differences between alleles is ignored, and sequences are given different allele 
numbers whether they differ at a single nucleotide site or at many sites. The rationale for this 
is that a single genetic event resulting in a new allele can occur by a point mutation (altering 
only a single nucleotide site), or by a recombinational replacement that will often change 
multiple sites. Weighting according to the number of nucleotide differences between alleles 
would imply that the latter allele was more distantly related to the original allele than the 
former, which would be true if all nucleotide changes occurred by mutation, but not if the 
changes occurred by a recombinational replacement [38;39].  
Nucleotide sequences of alleles and sequence types (STs) are available at 
http://mlst.net, and as of October 2008, 408 unique STs are registered in the GBS database 
(http://sagalactiae.mlst.net).  
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Analysis of MLST data                                                                                                            
There are several approaches that can be employed in analysing the genetic relationship 
between isolates analysed by MLST, two commonly used are: 
• Approaches that determine relationships on the basis of allele designations and STs 
(e.g. eBURST, based upon related sequence types)  
• Approaches that analyse nucleotide sequences directly (e.g. Neighbour joining 
method). 
 
Distance methods                 
UPGMA and Neighbour Joining methods are methods for the construction of dendrograms 
(phylogenetic trees) by converting aligned sequences into a distance matrix of pairwise 
differences (distances) between the sequences. UPGMA constructs clusters by assuming that 
all sequences are equally distant from a root, which is unlikely. The Neighbour Joining 
method is based on a distance matrix similar to UPGMA, but it calculates distances directly to 
internal nodes [40]. Figure 2 shows a phylogenetic tree constructed by the Neighbour Joining 
method. The different STs at the ends of the branches are called external nodes. The lengths 
of the branches between the nodes illustrate the differences in nucleotide sequences between 
the STs. Thus, the tree illustrates phylogenetic relationships between the sequence types.  
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Figure 2 A phylogenetic tree (Neighbour Joining) of STs with corresponding clonal 
complexes (CC) (see Figure 3) constructed from MLST analyses of invasive GBS from 
infants in Norway 2006 and 2007 (Data from Paper II). 
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eBURST                                               
eBURST analysis focuses on identifying groups of closely related isolates (clonal complex, 
CC) within a bacterial population which is assumed to share a recent common ancestor, and 
on exploring how these may have emerged and diversified [41]. eBURST divides a MLST 
data set of any size into groups of related isolates and clonal complexes, predicts the founding 
(ancestral) genotype of each clonal complex, and computes the bootstrap support for the 
assignment [41]. (Bootstrap is a way of estimating the reliability of the model by finding the 
sampling distribution, at least approximately, from just one sample) [40]. The most 
parsimonious patterns of descent of all isolates in each clonal complex from the predicted 
founder(s) are then displayed geographically (Figure 3). 
Isolates that share identical alleles at six of seven loci, and only differ from each other 
at one allele, are designated single-locus variants (SLVs). Isolates with five out of seven 
shared alleles are called double-locus variants (DLVs). The diagrams in Figure 3 represent 
clonal complexes (CCs). CCs are composed of a “founder” which is defined as the ST that has 
the greatest number SLVs. If two STs have the same number of associated SLVs, the one with 
the greatest number of DLVs is selected as the founding ST. 
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Figure 3 eBURST diagrams of groups of closely related isolates (clonal complexes, CCs) of 
invasive GBS strains from infants in Norway. The blue circles represent the founders or 
ancestral types which have given rise to descendent sequence type strains (black and yellow 
circles). The STs that are directly connected to the founders differ from the founder in only 
one single locus or allele and are called single locus variants (SLVs). STs that do not cluster 
into a clonal complex are called singleton STs (e.g. 361, 363, 24, and 345). The diameter of 
the founder circles is just illustrating the number of strains with that particular ST in our 
sample (Data from Paper II). 
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Invasive neonatal infections  
 
 
Definition of neonatal sepsis                          
Neonatal sepsis refers traditionally to sepsis in newborn babies during the first month of life. 
However, increased survival of immature and premature babies has resulted in a large group 
of infants with a high susceptibility to infections for a long time after birth, and the inclusion 
period for neonatal sepsis and meningitis often covers the whole hospital period [42]. 
Neonatal sepsis may be classified according to the time of onset of the disease; early onset 
disease (EOD) and late onset disease (LOD). This distinction has clinical relevance as EOD is 
mainly due to bacteria acquired before and during delivery, and LOD to bacteria acquired 
after delivery (from nosocomial or community sources). Unfortunately, there is no consensus 
as to what age limits apply, making it difficult to compare studies where cases are grouped 
into EOD and LOD without further details. In most literature on GBS, EOD is 0-6 days and 
LOD 7-90 days after birth.  
  
Sepsis, SIRS                                                                                                                            
The terms “sepsis” or “septicaemia” are traditionally used for isolation of bacteria in blood in 
combination with clinical symptoms. The term SIRS (systemic inflammatory response 
syndrome) was originally proposed to describe the non-specific inflammatory process 
occurring in adults after trauma, infection, burns, pancreatitis and other diseases. The criteria 
for use in adults have later been modified for use in children and infants, and include a core 
temperature >38.5 ºC or <36 ºC, tachycardia, increased respiratory rate and an elevated or 
depressed leukocyte count [43]. Sepsis may be defined as SIRS in the presence of or as a 
result of suspected or proven infection. Severe sepsis is defined as sepsis plus one of the 
following; cardiovascular organ dysfunction or acute respiratory distress syndrome or two or 
more other organ dysfunctions. Septic shock is defined as sepsis and cardiovascular organ 
dysfunction [43].   
 
Impact of neonatal sepsis                                                                                                         
In developing countries the neonatal mortality rate ranges from 17 to 68 per 1000 live births 
in the first 28 days, and one third of these deaths are caused by infections [44]. Sepsis and 
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meningitis are responsible for most of these deaths. In developed countries, neonatal mortality 
is 2-5/1000 live births and 10% is caused by infection [45]. According to WHO, there was an 
estimated number of neonatal deaths, caused by infection, of 382000 (3.4% of all deaths) in 
Africa in 2004. In Europe the estimated number was 27000 (0.3% of all deaths). However, it 
is generally assumed that neonatal mortality in developing countries is under-reported by at 
least 20% (WHO 1996).  
Neonatal infections represent a threat to neonatal health and take large health 
resources even in developed countries. In Norway, approximately five percent of neonates are 
transferred from the maternity wards to neonatal intensive care units for observation, 
diagnostics and treatment of possible infections (H.Døllner, personal communication).     
 
Aetiology and predominant pathogens of neonatal sepsis 
In developing countries, it appears to be a wide variety of bacteria causing EOD and LOD.  In 
most studies, Gram-negative organisms are predominant. Among Gram-negative organisms 
Klebsiella spp., Escherichia coli, Pseudomonas spp. and Salmonella spp. are the most 
reported. Among Gram-positive bacteria Staphylococcus aureus, Coagulase negative 
staphylococci (CoNS), Streptococcus pneumonia and Streptococcus pyogenes are the most 
reported species [44]. This variation may be true, but important confounders may include 
different definitions of EOD and LOD, different inclusion criteria for studies (including 
population sampled), inability to culture certain organisms, small numbers, and/or short 
periods of surveillance. The latter may be particularly important, as surveillance may be 
occurring during, or indeed may have been initiated because of, an outbreak of a specific 
pathogen and may not therefore be representative. 
Organisms responsible for neonatal infections in developed countries have changed 
the last decades (Table 2). While S. pyogenes and S. pneumoniae constituted half of the cases 
at Yale from 1933 to 1943, no cases caused by these bacteria were detected in the period 
1989-2003 [46]. Following the introduction of sulfonamides and penicillin, Gram-negative 
bacteria, and in particular E. coli, became predominant in neonatal infections. From the 1970s 
GBS emerged as the predominant microbe, and especially the first 24 hours after birth [4;46-
49] (Figure 4). In the last twenty years Gram-positive organisms have dominated both EOD 
and LOD in term infants, while E. coli have been more common in premature infants [48-51].  
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Some recent studies have shown a declining incidence of EOD in infants born after 37 weeks 
gestational age and also a declining incidence of invasive GBS disease [4;52]. Infections 
caused by CoNS have increased, and especially in LOD.  
The decline of EOD may be related to improved perinatal care of infants at risk and 
increased use of antibiotic prophylaxis to pregnant women and in neonates. On the other side, 
the improved neonatal care has also led to increased survival of immunocompromised 
immature and premature neonates susceptible to late onset infections like CoNS. CoNS are 
considered as opportunistic pathogens with increased virulence in immunocompromised 
patients, and they are also associated with the use of central venous catheters for patients with 
severe underlying conditions [48]. 
 
 
 
 
 
Table 2 Different studies on organisms isolated from blood cultures of neonates with sepsis  
 
 
Period 
 
Predominant pathogens  
 
references 
 
1928-1958 
 
S. aureus, E. coli, S. pneumoniae, S.pyogenes 
 
[46] 
 
1959-1965 
 
E. coli, Klebsiella spp., Pseudomonas spp. 
 
[46] 
 
1966-1988 
 
GBS, E. coli 
 
[46] 
 
1989-1995 
 
CoNS*, GBS, E. coli, Enterococcus spp., S. aureus 
 
 
[46;53] 
 
1996-2006 
 
CoNS*, GBS, E. coli, viridans streptococci, 
Enterococcus spp., S. aureus 
 
 
[4;46;48] 
*Coagulase-negative staphylococcus 
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Figure 4 Cases of early-onset disease by pathogen and day of onset. (Results from a 
multicenter surveillance in USA during 1995 to 1996 for culture-confirmed, early-onset sepsis 
in an aggregate of 52 406 births; matched case-control study of risk factors for GBS and other 
sepsis) [54].     
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Invasive GBS disease in infants 
 
 
Early onset GBS disease (EOD) 
EOD (age at onset 0-6 days) almost always manifests itself within 24 hours of birth (median 
age 8 hours in 90% of cases, 5% appears during 24-48 hours) [55]. In premature infants, onset 
of symptoms is often within 6 hours of birth. GBS colonisation in pregnant women is the 
single most important risk factor for early onset newborn disease due to vertical transmission 
and colonisation of the infant during delivery. 
The most common manifestations of EOD are septicaemia, pneumonia and meningitis. 
Irrespective of site of involvement, respiratory signs (apnoea, grunting respirations, tachypnea 
or cyanosis) are the clinical findings in more than 80% of neonates, and they can be difficult 
to oxygenate [55;56]. A differential diagnosis of GBS sepsis is RDS (Respiratory distress 
syndrome). Also radiographically, features consistent with and indistinguishable from those 
of hyaline membrane disease are present in more than one half of neonates with GBS and 
pulmonary infection. Treatment with surfactant improves gas exchange in a majority of these 
infants, although the response is slower than in non-infected infants [57].  
Other associated signs include lethargy, poor feeding, hypothermia or fever, 
abdominal distension, pallor, tachycardia and jaundice. Hypotension is an initial finding in 
approximately 25%. Infant with foetal asphyxia related to GBS infection in uteri may have 
shock and respiratory failure at delivery. Meningitis is seen in 5-10% of neonates with EOD, 
most of them present with the same symptoms as those without meningitis.  
 
Late onset disease (LOD)  
LOD affects the infant from 7 days to 90 days of age. Nosocomial infection of premature 
infants in neonatal intensive care units (NICU) and transmission of virulent GBS strains from 
mother to infant via skin or breast milk might explain some of the cases. However, most 
infants with LOD have no known risk factors and an uneventful early neonatal history, and in 
most of these infants the mechanisms of infection are not revealed [55].  
LOD often presents with hypothermia or hyperthermia, hyperglycaemia or irritability. 
Grunting respiration and apnoea are less frequent initial findings than in EOD [46]. 
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Meningitis is a frequent clinical manifestation, occurring in estimatedly 35-50% of cases 
[55;58].  
 
Antimicrobial therapy of GBS disease in neonates 
Most invasive GBS strains have been, and still are susceptible to penicillin G [59;60]. Most 
strains are also susceptible to ampicillin, semisynthetic penicillins, vancomycin, linezolid, 
trimetoprim sulfametoxazol and first, second and third generation cephalosporins [60]. 
Resistance to erythromycin and clindamycin has increased during the last decades [61]. In 
several studies, most GBS strains show resistance to tetracyclines, metronidazole and 
aminoglycosides [55;60]. However, if aminoglycosides are combined with penicillin, an in 
vitro and also an in vivo synergy effect, often is observed [62]. Despite their uniform 
susceptibility to penicillin G, GBS require higher concentrations for growth inhibition in vitro 
than are required for strains belonging to group A streptococci [63]. Although some studies 
indicate that 6-7 days therapy might be sufficient for uncomplicated bacteraemia [64], 
recommended duration of treatment of GBS infections has been 10-14 days for bacteraemia 
without focus or with soft tissue infection, 2 to 3 weeks for meningitis or bacterial arthritis 
and 3 to 4 weeks for osteomyelitis. 
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Epidemiology of invasive GBS disease   
 
 
Most reports on the incidence of invasive GBS disease in infants are based on blood or 
cerebrospinal fluid culture proven cases. Reports may be active laboratory based surveillance 
in certain areas during months or years, nationwide prospective studies or continuous 
surveillance of GBS disease where laboratories and or clinicians report to central registers. 
Retrospective search in local databases and registers of clinical diagnoses from hospitals 
(ICD-9, ICD-10) have also been published as well as questionnaires to clinicians and 
laboratories. 
 
Incidence of early onset disease (EOD)                                     
In most reports, EOD constitutes 60-80% of total invasive GBS disease in infants. Published 
data from USA and Australia from the late 1970s to the early 1990s show incidences of EOD 
of 1-3/1000 live births (Table 3). After 1996 the incidence seemed to drop, and after 1998-
2000 the average incidence has been around 0.5/1000 live births. The incidence of invasive 
GBS disease among newborns in USA has been higher in infants of African-American 
women than in infants of white and Hispanic women [65]. The reported incidences of EOD in 
Scandinavia were mainly lower than in USA and Australia until the late 1990s. After the 
middle of 1990s the incidences dropped in both USA and Australia and have been similar or 
lower than in Scandinavia and Europe after 2000 (Table 3 and Figure 5). In Europe outside 
Scandinavia, most reports are from late 1990s and after 2000 and the incidences of EOD are 
similar to what have been reported from Scandinavia [16;53;66-69].  
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Table 3 Reported incidences of early onset GBS disease in neonates (cases per 1000 live births 
per year) in different geographic areas in the period from 1975 to 2007  
 
Year 
 
1975 - 1980 - 1985 -  1989  -  1991 -  1993 -  1995   -   2000    -    2007 
 
 
References 
 
USA 
 1.09 1.5 -
3.21 
1.4 -1.7 1.3 -1.95 0.23 -
0.72 
0.33 -
0.47 
 
[56;65;70-76] 
Australia    1.45 0.84 0.3  [77;78] 
Sweden 0.1-0.5-1.24              0.78 0.40  [53;67;79;80] 
UK      0,48  [68] 
Norway  0.2 0.37 0.54 0.46 [16;81] 
New Zealand      0.5  [82] 
The 
Netherlands 
     
0.9 
 
0.43 
  
[58;83] 
Canada      0,9  [84] 
Germany      0,28  [66] 
Finland   0.63  0.65  [69;85] 
S Africa      2.06  [86] 
Denmark    1.5           0.73   [87] 
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Figure 5 Incidence (cases per 1000 live births) of early onset disease in USA and Norway by 
year, and from 2000 also by race in USA [16;65;72;81].  
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Incidence of late onset disease                                                                                                   
Even if incidence of EOD has changed through the last decades, the incidence of LOD has 
been quite stable. A common interpretation of this is that the different strategies to prevent 
GBS disease in infants have affected EOD only. 
  
GBS meningitis   
Two studies from England and Wales in the periods 1985-87 and 1996-97 showed an overall 
incidence of neonatal meningitis of 0.22 cases per 1000 live births. GBS was the leading 
pathogen responsible for meningitis (39% of cases in 1985-87 and 48% in 1996-97) followed 
by E. coli [88]. No significant change of incidence was observed between the two periods. 
Data from these studies were consistent with other published studies from the same period 
[89]. Later, a study from Australia suggested a decrease of neonatal meningitis in general and 
especially GBS meningitis, in the period from 1992 to 2002 [90].  
 
Case fatality of invasive GBS disease in infants 
The case fatality rate of invasive GBS disease was almost 50% in 1960s and early 1970s 
(Figure). After 1990 the rate has stabilised and has been reported from 4% to 7.5% [16;58;66-
69;72;91-94]. The case fatality is reported to be significantly higher in preterm infants [91], 
while LOD has a lower fatality rate (2-6%) than EOD. 
There are few studies on case fatality in developing countries, but a study from South 
Africa reported an incidence of EOD and LOD of 2.06 and 1 per 1000 live births, while the 
case fatality was 19.8% and 13.6% for infants with EOD and LOD, respectively [86].  
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Figure 6 Case fatality rate of invasive GBS disease in infants reported from Yale University 
School of Medicine, New Haven, USA [46] (Figure reprinted with permission) 
 
 
 
Morbidity and sequelae of invasive GBS disease in infants 
There are only few studies on long term disabilities of invasive GBS disease. Mild disability 
has been defined as having a condition which is prevalent among children of the same age, 
but not typically associated with meningitis (middle-ear disease, squint, febrile convulsions, 
behavioural problems). Moderate disability impairs functioning, but is not severe. The child 
can attend mainstream school with or without additional support. Moderate disability includes 
mild neuromotor disability, intellectual impairment, and epilepsy controllable by treatment, 
and hydrocephalus without complications. Children with severe disability are unable to attend 
mainstream school and/or have severe motor impairment, significant intellectual impairment, 
severe seizure disorders, and severe visual or auditory impairment [95]. 
Reports from UK have shown 25% disability from GBS bacteraemia, with severe 
disability in 7.0%, moderate disability in 13.9% and mild disability in 4.5% of the infants 
[96]. In infants with neonatal meningitis due to GBS, disability in 50% has been reported. 
This included severe disability in 13.3%, moderate disability in 17.3% and mild disability in 
18.4% of the infants [88;89;97]. The most commonly reported sequelae from meningitis have 
been cerebral palsy, blindness, deafness and hydrocephalus [89]. A retrospective study of 78 
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patients with EOD in the Netherlands found that the sequelae occurred mostly in patients with 
symptoms of GBS infection within six hours after birth. Early treatment of sick infants 
resulted in lower lethality, but not in less sequelae [98]. 
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Pathogenesis of neonatal GBS infections and virulence factors of 
GBS 
   
 
GBS can reach the foetus in uteri through ascending infection of the placental membranes and 
amniotic fluid. Alternatively, the newborn may become contaminated with the organism on 
passage through the birth canal. Invasive neonatal disease may be caused by both virulence 
factors in GBS and host factors. 
The GBS virulence includes factors that obstruct immunological defence mechanisms 
and the ability to penetrate epithelial and endothelial cellular barriers to reach the bloodstream 
and deeper tissues. GBS produce toxins that directly injure or disrupt host tissue, and also 
produce factors that provoke inflammatory pathways which may aggravate the disease 
[99;100]. GBS colonisation of pregnant women and lack of maternal antibodies to GBS are 
also important factors contributing to invasive neonatal disease. (An outline of stages in 
molecular and cellular pathogenesis of neonatal GBS infection is shown in Figure 7). 
  
 
Colonisation of the female genital tract                                                                           
Maternal vaginal colonisation with GBS is essential for both early colonisation of the 
newborn infant and EOD. There is also a relationship between the degree of vaginal 
colonisation (the inoculum size) and risk of vertical transmission of GBS and risk of disease 
in the newborn [101]. The gastrointestinal tract is the primary reservoir of GBS, and vaginal 
colonisation probably represents dissemination from this source [65]. 
  
 
Adherence to human cells                                     
To establish colonisation, GBS bind efficiently to human vaginal cells, with maximal 
adherence at the acidic pH characteristic of vaginal mucosa. The ability of adherence to other 
human cells like alveolar epithelium and endothelium and brain endothelium is probably also 
important for the pathogenesis of neonatal sepsis [102]. Molecules that appear to play an 
important role in adherence are the surface proteins, C5a peptidase (a bifunctional protein, 
which enzymatically cleaves C5a and mediates adherence to fibronectin) and laminin-binding 
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protein in the bacteria and in addition extra-cellular components as fibronectin in the host 
[99;100].  
 
Penetration of host cellular barriers                                                                                   
GBS can traverse and penetrate intact placental membranes, weaken their tensile strength and 
promote rupture and premature delivery by several mechanisms [103]. The bacteria 
proliferate easily in the uterine cavity and a large inoculum can therefore be swallowed by the 
foetus and delivered to the foetal lung. GBS spreads from the initial pulmonary focus to the 
bloodstream and is circulated through other organs and tissues. An important factor in the 
cellular damage is β-haemolysin/cytolysin. The cytolytic, proinvasive and proinflammatory 
effects of GBS are partly neutralized by dipalmotyl phosphatidylcholine (DPPC), the major 
phospholipids constituent of human lung surfactant [104]. This may in part explain the 
elevated risk of premature surfactant-deficient neonates to suffer severe GBS lung injury and 
invasive disease. Cellular invasion is shown to correlate with the virulence potential of GBS 
strains. Clinical isolates of GBS from infants with invasive GBS disease invade epithelial 
cells better than strains from the vaginal mucosa of asymptomatic women [105].  
 
Direct cytotoxicity to host phagocytes and inactivation of complement                                                         
The cylE –encoded β-hemolysin/cytolysin toxin, which is associated with the bacterial surface 
membrane [106], produces direct cytolytic injury to macrophages and induces macrophage 
apoptosis [107]. GBS also contribute to poor mobilisation of neutrophils by production of C5a 
peptidase, an enzyme that cleaves and inactivates human C5a, a complement component that 
is important in neutrophil chemotaxis [108].  
 
Impairment of myocardial function                                                                                                       
GBS directly impairs cardiomyocyte viability and function through β-hemolysin/cytolysin 
that possibly affects maintenance of normal calcium in intact cardiomyocytes and potentially 
leads to cell death. Experiments in rabbits have shown that infusion of GBS leads to lower 
cardiac output and decreased mean arterial pressure. This is caused by myocardial dysfunction 
rather than decreased vascular resistance [109].  
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Avoidance of the host’s defence mechanisms                                                                         
A number of virulence factors of GBS seek to prevent effective opsonophagocytic killing by 
the host. The most important virulence factor is the sialylated GBS polysaccharide capsule 
and surface proteins that can act in concert with capsular polysaccharide [110]. Serotype II 
strains displaying both components of the c protein antigen are more resistant to phagocytotic 
killing than are serotype II lacking c protein [111]. GBS have also been shown to penetrate 
and survive within several human cell types and especially within the phagolysosome of 
macrophages [112]. This capacity of cellular invasion may explain the ability of GBS to 
traverse placental membranes, the alveoli of the infant lung, and the neonatal blood brain 
barrier.  
 
Host factors                                                                                                                          
Phagocytic cells including neutrophils and macrophages are central in the immunologic 
response to the penetration of GBS into lung tissue or bloodstream of the newborn infant. 
Effective uptake and killing by these cells require opsonisation of the bacterium by specific 
antibodies in the presence of complement [110]. Neonates are particularly susceptible to 
invasive disease due to quantitative and qualitative deficiency in phagocytic cell function, 
specific antibodies, or the classic and alternate complement pathways. A significant 
transplacentally transfer of maternal antibodies does not begin until the third trimester of 
pregnancy, 60 % of maternally derived IgG is transported to the foetus during the last 10 
weeks of pregnancy [55]. Thus preterm infants are not protected by sufficient amounts of 
specific antibodies. Pregnant women without specific antibodies against GBS will also have 
babies who are more susceptible to GBS infections even if most infants born to women 
without specific antibodies remain healthy [55]. 
 
Activation of inflammatory responses                                                                                      
The clinical course of GBS sepsis and meningitis is dramatic with a high morbidity and 
mortality due to an excessive inflammatory response [55;113;114]. A powerful cytokine 
response and clinical signs of inflammation in neonates with GBS disease is in conflict with 
the picture of neonates as immunodeficient with impaired antimicrobial properties against 
GBS and tolerant to infective agents [114]. However, because the neonatal innate immune 
system is unable to eliminate GBS at the site of microbial invasion, a general inflammation 
with SIRS and sepsis is more likely to appear [113]. 
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Figure 7  An outline of stages in the molecular and cellular pathogenesis of neonatal GBS 
infection [115]  (Reprinted with permission).  
(β-H/C: beta-haemolysin/cytolysin. S.O.D.: superoxide dismutase. IL: interleukin. TNFα, 
tumour necrosis factor-alpha. PGE2: prostaglandin E2. TxA2:thromboxane A2. GROα: growth-
related oncogene-alpha. ICAM-1:intercellular adhesion molecule 1. GM-CSF:granulocyte-
macrophage colony-stimulating factor).  
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Risk factors for EOD  
 
 
GBS colonisation                                                                                                                      
Maternal vaginal colonisation with GBS is essential for both early colonisation of the 
newborn infant and the risk of EOD. Women with heavy (dense) colonisation are at greater 
risk of having an infant with EOD [101;116-121]. Reported colonisation rates in pregnant 
women vary from 10-35% (Table 4).   
  Racial differences in colonisation rates have been observed. A study from The 
Netherlands where the participating women originated from 72 different countries showed 
that Asian women had a lower colonisation rate and African women a higher colonisation rate 
than European women [125]. This coincides with studies from USA which have shown a 
higher colonisation rate in African American women than in white and Hispanic women 
[130]. 
 
Table 4 Prevalence of maternal colonisation of GBS in different countries 
 
 
Country 
 
1996-2006 
 
References 
 
Sweden 
 
25.4% 
 
[67] 
 
Norway 
 
34.8% 
 
[122] 
 
Germany 
 
16% 
 
[123] 
 
UK 
 
21.3% 
13.59% 
 
[96;124] 
 
The Netherlands 
 
21%  
 
[125] 
 
Iceland 
 
24.3% 
 
[126] 
 
Italy 
 
11.3% 
17.9% 
 
[127;128] 
 
 
USA 
 
21% 
 
[120] 
 
New Zealand 
 
20% 
 
[129] 
 
Zimbabwe 
 
24% 
 
R.Mawenyengwa 
(unpublished data) 
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Preterm and low birth weight (LBW) infants                                                                                              
Preterm and LBW infants have an increased risk of EOD with a progressive increase in risk 
for neonatal sepsis with decreasing gestational age (GA) and birth weight [101;121;131]. 
Hakansson et al showed that even infants born at 37 weeks GA had a three fold increased risk 
of EOD compared with infants born at 40 weeks [67].  
 
 
Prolonged rupture of the amniotic membranes                                                                                                
Prolonged rupture of the amniotic membranes (PROM) for >18-24 hours before delivery 
increases the risk of neonatal GBS disease. Large published series indicate that PROM >18 
hours occurs in 12.5% of deliveries and is associated with an OR of 7.28 (95% CI: 4.42-12.0) 
of invasive GBS disease [101;118;121;131;132]. 
 
Fever                                                                                                                            
Intrapartum temperatures >37.5ºC [132] and  >38.0ºC [133] are associated with an increased 
risk of neonatal GBS infection [54;101;118;132]. It is not known whether the risk of EOD is 
higher with a temperature of 40.0ºC than with a temperature of 38.5ºC [101].  
 
Chorioamnionitis                                                                                                              
Intrapartum fever accompanied by two or more additional signs, including foetal tachycardia, 
uterine tenderness, foul-smelling vaginal discharge, or maternal leucocytosis, occurs in 1.0 % 
to 3.8 % of deliveries. These symptoms are mainly due to chorioamnionitis which is 
associated with neonatal GBS disease rates ranging from 6% to 20% [101;121;132;134].  
 
 
GBS bacteruria                                                                                                                         
Infants born to women with GBS bacteruria during pregnancy are more frequently and more 
heavily colonised with GBS, and may be at increased risk for invasive GBS disease, however 
the different studies published are not conclusive [101;119;135].  
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Maternal antibodies   
An infant's susceptibility to GBS is increased when the level of anticapsular antibodies to the 
infecting serotype is low. This is the case when the maternal antibody level is low and also  
when infants are born before 34 weeks gestation, since transplacental transport of 
immunoglobulin G is reduced early in gestation [136;137]. 
 
 
Previous infant with invasive GBS disease 
Although having had a previous infant with invasive GBS disease is accepted as placing a 
mother at high risk in subsequent pregnancies, only a few instances have been reported in 
which neonatal GBS infection followed more than one pregnancy in the same mother 
[79;138]. However, women may remain colonised with the same strain of GBS for prolonged 
periods and may fail to develop protective levels of type-specific serum antibodies despite 
long-term colonisation [139]. It is therefore likely that the risk in subsequent pregnancies is 
higher for women who have had a child with EOD GBS disease, even if this risk cannot be 
quantified. 
 
 
Race                                                                                                                                           
Heavy colonisation with GBS has been identified more frequently in African American 
women than in white American women or Asian women. The incidence of EOD in African 
American infants is also higher. The higher colonisation rate may explain the higher risk of 
both early- and late-onset GBS disease among African Americans, but whether socioeconomic 
factors and differentiated health care also influence the risk of GBS disease is not known. In 
addition, findings of high colonisation rates in Scandinavian women may challenge the 
hypothesis of more GBS disease in populations with high colonisation rates [122;130;140]. 
 
 
Other risk factors                                                                                                             
Gestational diabetes [67] and frequent vaginal exams [54], are reported to increase the risk of 
having a baby with EOD.  
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Prevention of neonatal GBS infections 
 
 
 
Development of preventive strategies                                                                                    
The first attempt to prevent GBS disease in neonates was giving antepartum antibiotics to 
pregnant women colonised with GBS [141]. Oral and intramuscular regimens were tried, but 
were found to cause only a temporary drop in vaginal colonisation. It is believed that GBS 
remain in the colon and recolonise the birth canal once the antibiotics are stopped. In 1979 a 
report claimed that a single dose of ampicillin given to the mother intrapartum could interrupt 
the transmission of GBS from mother to baby [142]. Later, Boyer and Gotoff demonstrated a 
reduction in EOD if antibiotics were given intrapartum [143]. In early 1990s, guidelines for 
intrapartum antibiotics prophylaxis (IAP) were issued in North America. However, IAP use 
was not widely adopted and national standards for IAP administration were not implemented 
in USA until 1996, when CDC issued consensus guidelines recommending that health-care 
providers use either risk-based or culture-based screening to identify candidates for IAP. In 
2002, a population-based study, demonstrated that routine screening of all pregnant women at 
35-37 weeks' gestation and IAP for carriers prevented more cases of EOD in USA than the 
risk-based approach. This led to the universal prenatal screening recommendation in 2002 
[65]. In Norway, guidelines for prevention of GBS were issued in 1998 and new guidelines in 
2007/2008, recommending IAP to women with risk factors (www.legeforeningen.no). 
   
 
Risk factor based strategy                                                                                                            
In general, risk factor based strategies recommend IAP to women with prolonged rupture of 
membranes (>18-24 hours), gestation <37 weeks, intrapartum fever, previous GBS infected 
infant or GBS bacteriuria detected during the current pregnancy. However, this might be 
practiced differently in different countries. In Norway, IAP is recommended if GBS 
bacteriuria is detected during the current pregnancy, if the woman had a previous GBS 
infected infant, and if fever >38.0ºC. If GBS is detected by chance during the pregnancy, IAP 
is also indicated if labour starts before gestational week 37 and if prolonged rupture of 
membranes >18 hours. If there is premature rupture of membranes during pregnancy, culture 
and antibiotic treatment is recommended if GBS is detected (www.legeforeningen.no). 
 
 40
Screening strategy                                                                                                                     
In USA, rectovaginal specimens from pregnant women with gestational age 35-37 are 
cultured to detect GBS colonisation and IAP is recommended to colonised women. Figure 8 
and 9 show more details of the screening strategy. 
 
 
 
Figure 8 Screening strategy and indications for intrapartum antibiotic prophylaxis as 
recommended by CDC, 2002 [65]. 
 
 
Vaginal and rectal GBS screening cultures at 35-37 weeks gestation for all  
pregnant women (unless the woman had GBS bacteriuria during the current 
pregnancy or a previous infant with invasive GBS disease) 
Intrapartum prophylaxis indicated 
 
• Previous infant with GBS disease 
• GBS bacteriuria during the current 
pregnancy 
• Positive GBS screening culture during 
current pregnancy (unless a planned 
caesarean delivery, in the absence of 
labour, or amniotic membrane rupture, 
is performed) 
• Unknown GBS status and any of the 
following: 
 
-Delivery at <37 weeks 
gestation 
 
-Amniotic membrane rupure 
>18 hours 
 
-Intrapartum temperature 
>38ºC 
Intrapartum prophylaxis not indicated 
 
• Planned caesarean delivery 
performed in the absence of labour 
or amniotic membrane rupture 
(Regardless of maternal GBS 
culture status). 
 
• Negative vaginal and rectal GBS 
screening culture in late gestation 
during the current pregnancy, 
regardless of intrapartum risk 
factors 
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Figure 9 Regimens for intrapartum antibiotic prophylaxis as recommended by CDC [65]. 
 
 
 
 
 
 
 
 
 
 
 
 
Recommended: Penicillin G IV every 4 hours until 
delivery                      
 
Alternative: Ampicillin IV every 4 hours until 
delivery   
 
If penicillin allergic: 
  
Patients not at high  
risk for anaphylaxis:  Cefazolin IV every 8 hours until 
delivery   
 
Patients at high risk for  
anaphylaxis and GBS  
susceptible to clindamycin  
and erythromycin:  Clindamycin IV, every 6 hours until 
delivery or  
Erythromycin IV every 6 hours until 
delivery. 
 
GBS resistant to clindamycin 
or clindamycin or  
susceptibility unknown: Vancomycin every 12 hours until 
delivery             
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Methods for detection of GBS colonisation in pregnant women 
 
Culture                                                                                                                                     
The “gold standard” of GBS screening is culture performed at 35-37 weeks gestation from 
swabs collected from both the vagina and the rectum. The use of selective media (agar plates 
and broth) for culture supplemented by antibiotics like colistin (10 µg/ml) or nalidixic acid 
(15 µg/ml) are recommended [65]. The selective agar plates may be examined after 24 hours 
while the inoculated selective, enrichment broth is incubated for 18-24 hours and then 
subcultured onto sheep blood agar. If GBS is not identified after the incubation of 18-24 
hours, the blood agar plate should be reincubated and examined at 48 hours to identify 
suspected organisms. Suspected colonies may be tested using slide agglutination tests for 
specific identification [144]. Studies have shown that the use of standard direct blood agar 
plating rather than selective, enrichment medium leads to false negative culture results in as 
many as 50% of pregnant women colonised by GBS [144]. 
The culture taken at 35-37 weeks of gestation, may not accurately predict genital tract 
colonisation during labour because colonisation may be transient and colonisation may occur 
after the time of screening. Studies have shown sensitivities of a positive test (the ability to 
predict vaginal colonisation at time of labour) in week 35-37 from 54% to 91% [125] 
[101;145;146]. 
 
 
Antigen tests                                                                                                                          
GBS strains can also be identified by the production of group B Lancefield antigen [147]. 
Consequently, many latex agglutination tests and imunoassays that detect this antigen for 
GBS identification have been developed for rapid detection of GBS colonisations without 
previous culture. However, even if the specificity has been high (98-100%), the overall 
sensitivity of these commercially available immunological assays has been low and not 
sufficiently accurate for routine use in the intrapartum detection of women colonized with 
GBS [148]. 
 
DNA hybridisation                                                                                                               
Probe hybridisation for GBS targets specifically the GBS ribosomal RNA. The method has 
been shown to be suitable to identify GBS from 18h to 24 h cultures in selective enrichment 
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broth with a sensitivity of 94.7-100% and specificity of 96.9-99.5% compared with culture 
[149]. The sensitivity is much lower when incubation is shorter. Thus, available probe 
hybridization methods are suitable for GBS identification from overnight cultures in selective 
enrichment broth, but are poorly sensitive for direct detection and identification of GBS from 
recto vaginal swabs obtained from pregnant women during labour [149]. 
 
 
Polymerase chain reaction (PCR)                                                                               
Identification of GBS can be made by detecting a part of the DNA; the genetic target, which 
is unique for GBS. DNA extraction from GBS is dependent on lysis of the bacteria which 
sometimes may be challenging due to the robust polysaccharide capsule and cell wall of GBS. 
The PCR starts with the denaturation step where double-stranded target DNA is 
denatured (melted) into single stranded DNA by increasing the temperature to approximately 
95ºC. The temperature is then lowered to approximately 55-58ºC; this permits the annealing 
of the specific PCR primers to the single stranded target DNA. Finally, for efficient synthesis 
of DNA copies, the temperature is adjusted to be optimal for the DNA polymerase activity 
(extension), normally 72ºC (Figure 10). To amplify target DNA the cycles through these 
temperatures are repeated several times (25 to 40 depending on the application). During a 
successful PCR process, several millions copies of the target DNA (amplicon) are made. In 
conventional PCR the amplicon accumulation is usually detected by gel electrophoresis. In 
real-time PCR, the amplicon accumulation is detected and measured during each PCR cycle 
using a fluorescent reporter.  
Different PCR-based assays for identification of GBS have been developed. The 
assays are based on a variety of genetic targets. Examples are the cfb gene, which encodes the 
CAMP factor, the sip gene, encoding the surface immunogenic protein Sip, and ptsI gene 
(phosphotransferase) [122;150;151]. The PCR assays also differ by different lysis methods 
and different probe detection formats (TaqMan probes, fluorescence resonance energy 
transfer (FRET) probes or molecular beacons) [152].  Studies of different GBS specific PCR 
assays have shown that they are both sensitive and specific compared to culture 
[122;150;153;154].  
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Figure 10 General outline of the first three cycles in PCR. During the first three cycles of the 
PCR process, 22 copies of a part of the parental strands, defined by the specific primers, have 
been made. 
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Vaccines  
Maternal antibody deficiency to GBS is associated with increased neonatal susceptibility to 
invasive GBS disease [155]. Immunization of women during or before pregnancy could 
prevent peripartum maternal disease and protect infants from perinatally acquired infection by 
transplacental transfer of protective IgG antibodies [75;156].  
The group B antigen, which is common to all strains, does not seem to be important 
for specific immunity to GBS infection. Maternal antibodies against the group B specific 
antigen do not protect against neonatal infection [157]. However, serotype-specific antibodies 
to GBS capsular polysaccharide (CPS), have been shown to cross the placenta, promote 
opsonophagocytosis and killing of GBS [137;158].  
Early studies showed low immunogenicity in response to the polysaccharide capsule 
of GBS alone [159], but by combining the GBS polysaccharide with tetanus toxoid, an 
excellent immune response could be produced [156;160]. Also several of the surface protein 
antigens induce protective immunity in animal models [17]. Vaccine trials have shown that if 
surface proteins are conjugated to CPS, they enhance the immunogenicity of the CPS [161-
163]. Alternative approaches to vaccines are based on surface proteins of GBS [161;164], on 
the recognition of immunogenic pili that extend from the surface of the bacterium [164], and 
on fusion proteins [165]. A summary of the status of GBS vaccine research is presented in 
Table 4.  
A successful GBS vaccine could reduce mucosal bacterial colonisation and produce 
both humoral and mucosal immunity, and is expected to prevent more cases of neonatal 
disease than the current strategies with IAP [96;166]. However, trials of vaccine efficacy and 
safety are required for licensing of the vaccines. Such efficacy trials are likely to use substitute 
outcomes based on serological markers of a protective immune response, since trials to assess 
neonatal infection would need to be extremely large. Extensive post-marketing surveillance 
for effectiveness and safety would be an essential part of a licensing strategy. 
The prime obstacle to the development and testing of a GBS vaccine is probably the 
spectre of the liability associated with vaccine delivery in pregnant women [167;168]. 
Concerns for the safety of the mothers and foetuses require exhaustive and costly evaluation 
of candidate vaccines and the issue of liability is both serious and complex. Potential 
challenges other than medico-legal issues include lack of protection passed to infants born 
prematurely, the unknown effects on neonates’ immune responses and regulatory issues [169]. 
In order to successfully proceed in this field of maternal immunisation, it is necessary to 
define the actual risk, so that studies can be appropriately designed to demonstrate safety.  
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Studies of concerns that would be associated with GBS vaccination during pregnancy 
from the perspectives of pregnant women and health care providers have been performed 
[170]. Given all the factors involved in deciding whether to accept a vaccine or not, it 
appeared that being well informed about GBS was the most important factor. For any vaccine 
to be implemented, effective strategies for building public and individual trust are critical. 
These strategies need to be weighed against the pros and cons of the current IAP strategy as 
well as vaccination [170]. 
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Table 4  Summary of GBS vaccine research and development   
 
Vaccine target Advantages/approach Limitations 
 
Capsular carbohydrate 
  
Unmodified 
polysaccharide vaccine 
(type III serotype) 
Phase I trials (1988) indicated that the vaccine 
was safe and well tolerated [171] 
Only 60% of the recipients showed an 
immune response; Requirement to 
improve immunogenicity of the CPS 
Conjugate polysaccharide 
vaccine 
Type III serotype: increase in immunogenicity 
when coupled to an immunogenic protein 
(tetanus toxoid (TT)); Conjugate vaccine with 
all nine currently identified GBS serotypes 
(Ia, Ib, II, III, IV, V, VI, VII and VIII) 
prepared and tested preclinically [172-175] 
(1988-2002) 
Capsular conjugate vaccines of this 
type need to be multivalent in order to 
provide sufficient coverage against 
prevalent serotypes 
Conjugate bivalent 
polysaccharide vaccine 
Bivalent vaccine (GBS type II-TT and type 
III-TT) combined and administered; Well 
tolerated [176] (2002) 
Further testing is warranted to 
investigate immune interference when 
more than two GBS CPS conjugate 
vaccines are simultaneously 
administered 
Conjugate multivalent 
polysaccharide vaccine 
Proposed that effective GBS vaccine in the 
United States includes five major serotypes 
(Ia, Ib, II, III and V). It is anticipated that 
multivalent vaccines will include each 
conjugate vaccine prepared separately [176] 
(2002) 
Formulation of a GBS conjugate 
vaccine for use in one geographic 
area might not be effective in other 
regions 
Proteins   
C5a peptidase 
Present in all strains and serotypes of GBS; 
Little or no antigenic variability; Capable of 
inducing antibodies that are opsonically active 
[177]. Immunization induces serotype-
independent protection (2001) 
Progress as a potential vaccine is 
unknown 
 
β-Component of the c 
protein 
Elicits protective immunity in animal models 
[163] (1992) 
This protein is only present in a 
minority of strains that cause 
infection ( 20%) 
LmbP Expressed by most GBS strains (2005) Progress as a potential vaccine is unknown [178]. 
Sip 
Present on all GBS strains; Induces protective 
antibodies; Recombinant SIP protein 
protected mice infected with numerous GBS 
strains [179]  
Biological function is not well 
understood; No recent reports of 
progress towards the development of 
a vaccine [178;180;181]  
LrrG Highly conserved protein antigen that induces protection [182]. 
Progress as a potential vaccine is 
unknown 
Fusion protein from N-
terminal of Rib and α 
More immunogenic than one derived from the 
repeats and was immunogenic even without 
adjuvant (2007).  
Antibodies to the N-terminal fusion 
protein protected against infection in 
mice and inhibited bacterial invasion 
of epithelial cells [165]. 
PI-2b pilus antigens Present in all tested GBS strains, protective in mice (2008) [164]. 
Progress as potential vaccine is 
unknown 
 
CPS, capsular polysaccharide; LmbP, laminin binding protein; Sip, surface immunogenic protein. 
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Aims of the study 
 
 
• To survey the incidence of invasive GBS disease in infants and adults and detect 
possible trends in the distribution of capsular types, surface proteins and susceptibility 
to erythromycin and clindamycin in invasive GBS strains in Norway during the period 
1996 to 2006  
 
• To characterise isolates from infants with invasive GBS disease in Norway in 2006 
and 2007 by phenotypic and molecular methods and investigate whether phylogenetic 
lineages are associated with specific characteristics like antibiotic susceptibility, 
geographic origin, early or late onset GBS disease and lethality 
 
• To evaluate a real-time PCR targeting the sip-gene in detecting GBS colonisation in 
pregnant women at delivery and compare the performance with optimised GBS culture 
 
• To assess to what extent time affects the logistics of intrapartum screening and 
administration of intrapartum antibiotic prophylaxis and thereby the feasibility of 
intrapartum screening 
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Material and methods 
 
 
Study population                                                                                                                       
In Paper I-II, data on incidence of invasive GBS disease in the Norwegian population were 
obtained from The Norwegian Surveillance system for Communicable Diseases (MSIS), in 
Paper I from patients in all age groups and in Paper II from infants <3 months. The GBS 
strains from patients with invasive disease in Norway were sent from the laboratories at the 
respective hospitals to the reference laboratory at St. Olavs Hospital for further 
characterisation. For paper III, we collected specimens from 250 pregnant women at the 
maternity ward at St. Olavs Hospital, Trondheim, Norway. For paper IV, data on arrival at the 
maternity ward of 836 pregnant women, and time of delivery at St. Olavs Hospital, 
Trondheim, were analysed. 
 
 
Detection and identification of GBS                                                                               
Methods of detecting and identifying GBS from pregnant women and from invasive strains 
are described in paper I, II and III. 
 
Phenotypic characterisation of invasive GBS strains  
Capsular typing and typing of surface proteins were performed by indirect fluorescent 
antibody tests (FAT). From January 2006, these methods were replaced by PCR methods 
detecting capsular polysaccharide synthesis gene clusters and genes encoding surface 
localised proteins as described in paper I. The susceptibility testing of strains is described in 
Paper I and Paper II. 
 
Genotypic characterisation of invasive GBS strains 
Capsular typing and typing of surface proteins were performed by PCR methods detecting 
capsular polysaccharide synthesis gene clusters and genes encoding surface localised proteins 
as described in Paper I and Paper II. 
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MLST For each strain the seven housekeeping genes alcohol dehydrogenase (adhP), 
phenylalanyl tRNA synthetase (pheS), amino acid transporter (atr), glutamine synthetase 
(glnA), serine dehydratase (sdhA), glucose kinase (glcK), and transketolase (tkt) were 
amplified and sequenced using primers and conditions as described by Jones et al [183].  
Sequencing was performed using the BigDye terminator Cycle Sequencing Kit v 3.1 (Applied 
Biosystems) followed by capillary electrophoresis on ABI 3130x Genetic Analyzer. The 
sequence traces for each of the seven gene loci were assigned an allele number, and each 
strain was assigned a sequence type (ST) according to allelic profile, by submission of the 
sequences to the S. agalactiae MLST database. Genetic comparison of the strains was 
performed by constructing a dendrogram showing the relationship among STs using MEGA3 
(version 3.1) [184]. Strains were grouped into clonal complexes (CC) using the eBURST 
software program [41]. The term singleton ST refers to STs that did not cluster into a clonal 
complex (CC).  
 
PFGE Bacterial chromosomal DNA was digested with SmaI [185], before separation by 
electrophoresis using the CHEF XA Mapper (Bio-Rad. Richmond, CA, USA). The PFGE 
profiles were compared both by manual inspection and by cluster analysis using Bionumerics 
(version 5.10, Applied Maths, Sint-Martens-Latem, Belgium).  
 
 .  
Decision and cost effectiveness analysis                                                                                           
In the decision analysis (Paper IV), a complex “decision tree” was modelled by means of the 
software program, TreeAge Pro version 1.2 (Tree Age Software, Inc., Williamstown, MA). 
The “decision node” was the choices between three different strategies: No intervention, 
antepartum screening and intrapartum screening. There were five principal outcomes of the 
strategies; no GBS disease, full recovery after invasive disease, moderate disability after 
invasive disease, severe disability after invasive disease and death due to invasive disease 
(Figure 11). The different strategies included many possibilities of outcome and in the model 
there are 63 chance nodes and 126 different outcomes. 
The information obtained in the cost effectiveness analysis was the cost of gaining one 
quality adjusted life year (QALY) when a health intervention is applied and compare the cost 
per QALY for different strategies. The number of QALYs gained by an intervention 
represents the number of years of perfect health that would be obtained by providing that 
intervention. To differentiate between a year of life gained and a healthy year of life gained, 
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one must consider the effects of disease on both quantity and quality (utility) of life 
separately. In short: individuals who consider themselves to be in perfect health would rate 
their utility as one, while someone who would just as soon be dead might rate his or her life as 
a zero. Someone with a chronic debilitating disease might rate (utility score) her life as 0.7, 
indicating that she values her life as only worth seven tenths of  a year lived in perfect health. 
The total number of QALYs in a health state is equal to the product of utility score and the 
number of years lived in that health state. An infant with a serious neurological handicap due 
to invasive GBS disease as newborn might have both a life expectancy that is shorter than a 
healthy infant and also a lower quality of life. In the cost effectiveness analysis, the cost of an 
intervention (“No intervention”, “culture strategy” or “PCR strategy”), the quality of life, and 
the number of years of life gained were combined into a single cost effectiveness ratio. Cost 
effectiveness threshold or willingness to pay (WTP) represents the price which the society is 
willing to pay to gain one QALY. 
 
 
Equation1: Cost effectiveness ratio: 
 
cost of intervention (screening, antibiotics) – costs prevented by intervention                                                    
     QALYs gained by intervention 
 
 
 
In the study, comparisons between interventions were made using the incremental cost 
effectiveness ratio which is defined as  
Equation 2: Incremental cost effectiveness ratio: 
 
total cost of intervention 1 – total cost of intervention 2                                                              
QALYs, intervention 1 – QALYs, intervention 2 
 
 
 
In paper IV, reference values for life expectancy and quality of life (utility scores) 
were obtained from published studies that reported utility values during childhood associated 
with disability due to meningitis or bacteraemia as summarised and presented in one 
comprehensive study [96].  
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Figure 11 General outline of the decision model. The three strategies have all five end points. 
The costs included in the model are costs of screening and potential intrapartum antibiotic 
treatment of GBS colonised mother and hospital costs of a healthy or sick infant. 
Effectiveness is quality adjusted life year (QALY) of either a healthy or sick infant. Variables 
like risk of GBS colonisation of women, risk of invasive disease either sepsis or meningitis if 
colonised, time for intrapartum prophylaxis if intrapartum or antepartum screening, sensitivity 
of different screening methods and effect of antibiotic prophylaxis given 1-2 hours or more 
than 2 hours before delivery are not shown in this figure. 
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Ethics 
The study on GBS colonisation in pregnant women was reported to the Norwegian Social 
Science Data Services, and was approved by the Regional Committee for Medical Research 
Ethics. A research bio-bank was approved by The Norwegian Directorate for Health and is 
registered at The Norwegian Institute of Public Health.  
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Statistical analyses 
Categorical data were compared by Chi-square or Fisher’s exact tests. 
Data on detection of GBS colonisation and data on interval between admission and delivery 
and time for intrapartum screening were collected and analysed in SPSS (SPSS Inc, Illinois, 
USA). Data on incidences of invasive GBS disease and data on GBS typing were collected 
and analysed in Windows Excel.  Minitab and Pearson’s Chi-square test were used for 
comparison of incidence in the two periods 1996-2000 and 2001-2006 and for comparison of 
proportions of serotypes. In cost effectiveness analyses, the analyses were performed with 
TreeAge Pro version 1.2 (TreeAge Software Inc., Williamstown, MA).   
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Results 
 
 
 
Paper I: The overall mean incidence of GBS disease in adults (>19 years) increased from 
1.34 cases per 100 000 in 1996-1998 to 3.1 cases per 100 000 in 1999-2006 (p <0.001). The 
mean incidence in elderly (>70 years) increased from 3.9 per 100 000 in 1996-1998 to 9.15 in 
1999-2006 (p <0.001). The incidence of neonatal early-onset disease was stable during the 
period with 0.46 cases per 1000 live births. The case fatality of GBS disease in infants was in 
average 6.5% in 1996-2005. However, in 2006 the case fatality increased to 20%.  Serotype 
III and V were predominant in 839 invasive GBS strains characterised; type III in infants and 
type V in the elderly. The distribution of surface proteins was stable from 1996 to 2005, but 
the detection rate of surface proteins in type III and V was low. Genes encoding surface 
proteins were detected in nearly all strains from 2006. The resistance to erythromycin and 
clindamycin increased from an average of 4% of invasive strains in the period 2003 to 2005 to 
25.4% resistant strains in 2006.  
 
 
Paper II: 96 GBS strains from nearly all infants registered with invasive disease in Norway 
2006 and 2007 were characterised by phenotypical and molecular methods. MLST identified 
27 sequence types and five clonal complexes (CCs): CC17, CC1, CC19, CC358 and CC23 
which is similar to what has been observed in previous studies from other countries. Resistant 
strains were found in CC1 and CC19. PFGE performed on all serotype V strains identified 10 
PFGE patterns belonging to four different clusters. The erythromycin and clindamycin 
susceptibility of each strain appeared to be associated with its PFGE cluster profile. There 
also appeared to be an association between PFGE profile and early and late onset disease. 
MLST data did not correlate with phenotypical characteristics of invasive GBS strains from 
infants in Norway.  
 
 
Paper III: The performance of a real-time PCR targeting the sip gene for detection of Group 
B streptococcus (GBS) colonisation in pregnant women at delivery was compared with 
optimised culture. Of samples from 251 women, 87 (34.7%) were GBS positive by culture 
and 86 (34.3%) were PCR positive. Using GBS culture as gold standard, the sensitivity of 
real-time PCR was 0.97 (95% CI: 0.90-0.99), and specificity was 0.99 (95% CI: 0.97-0.99).  
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The rate of GBS colonisation was lower in vaginal specimens than in rectal specimens both 
by culture and PCR. Real-time PCR targeting the sip gene was found to be fast and sensitive, 
well adapted for detection of GBS colonisation in pregnant women at term. 
 
Paper IV Logistics of intrapartum screening and intrapartum antibiotic prophylaxis to 
pregnant women colonised with GBS were studied. Decision analysis was applied to compare 
cost effectiveness of antepartum culture at gestational week 35-37 and intrapartum PCR in 
screening for GBS. Of 836 registered pregnant women, 78.5% arrived before the four hours 
set as a minimum for providing intrapartum screening logistics and effective antibiotic 
prophylaxis. Depending on frequency of analyzing runs in the laboratory, 46% to 78.5% of 
the women could receive adequate antibiotic prophylaxis if intrapartum screening was 
performed. If “willingness to pay” (WTP) was at least $10972/QALY, both antepartum and 
intrapartum screening strategies were cost effective compared to no intervention. Culture was 
the most cost effective screening strategy, but PCR would give the best clinical outcome. 
However, the incremental cost/effect of PCR compared to culture was very high 
($101153/QALY), and much higher than the established cut-offs for WTP ($50000/QALY - 
$70400/QALY). 
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Discussion 
 
Epidemiology of GBS  
While the incidence of EOD in Norway seemed to increase between 1985 and 1994, it 
stabilised and was unchanged from 1996 to 2006. The reported incidences of invasive GBS 
disease may be biased by different factors. In Norway, several neonatal units were established 
at the hospitals after 1980 and improved the neonatal care throughout the country. This may 
have enhanced the quality of diagnostics and increased the number of septic infants with a 
correct diagnosis. Thus, some of the observed increase in incidence of GBS disease in 
Norway from the late 1980s to the mid 1990s may be explained by structural changes of the 
health care system and not by a change of epidemiology. Another bias in statistics of neonatal 
disease, both in Norway and in other countries, is the neonatal sepsis of unknown aetiology. 
Bacterial growth is detected in less than 10% of blood cultures from sick neonates [186], and 
most infants treated for a neonatal infection are discharged from the hospitals with the 
diagnosis “unspecified sepsis in the newborn” (Figure 12).  
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Figure 12 Cases with diagnosis P36.0 (GBS disease in newborn) and P36.9 (Sepsis in 
newborn, unknown cause) and cases of invasive GBS disease in infants <1year reported to 
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MSIS (Sources: Norwegian Patient Register and Norwegian Surveillance system for 
Communicable Diseases (MSIS)) 
Studies have suggested that the incidence of invasive GBS disease, if based on additional 
criteria other than culture, is at least three times higher than the incidence based on culture-
proven cases [58;67;187]. Estimates of “true incidence” of invasive GBS disease are 
important in the context of both the burden of disease and for health policy issues, but might 
be less suitable for epidemiological studies. Local diagnostic routines and traditions, changing 
systems of health service financing, more focus at GBS disease in media and among 
paediatricians, gynaecologists and microbiologists might influence what diagnoses are being 
used. The ambiguity of incidence reports makes explanations of trends in GBS disease and 
differences between countries uncertain and incomplete. This also makes it more difficult to 
estimate the effect of different strategies to prevent EOD.  
 
A recent change in virulence of GBS strains in Norway?  After the dramatic rise of case 
fatality of GBS in Norway in the first half of 2006, a survey of GBS cases in search for 
possible explanations was carried out by The National Institute of Public Health [188]. The 
survey did not reveal any single explanation of the increased lethality, but suggested that a 
more virulent serotype V could explain some of the fatal cases.   
Type V emerged as an important serotype in invasive strains from neonates and adults 
in the 1990s and is now in some areas the most common serotype in adults [75;189]. In our 
material from 1996 to 2006, type V was detected in 10% of strains from infants and in 24% of 
strains from adults (Paper I). In 2007, 19% of invasive strains from infants had capsular type 
V (Paper II). In addition to be the cause of five neonatal deaths in 2006 and 2007, type V has 
also shown more resistance to erythromycin and clindamycin from 2005 on. In GBS strains 
from infants, 61% of type V strains were resistant in Norway, 2006 and 2007. 
It has also previously been shown significant antibiotic resistance in type V strains 
[61;190;191]. A study by Diekema showed that resistant type V strains from the 1990s in 
USA did not represent a new subtype of GBS V [192]; the resistant strains had the same or a 
very similar PFGE pattern as the most common type V registered by CDC already in 1975 
[193]. This subtype of type V has also been reported as common among type V strains in 
France and Germany [191;194] and in accordance with this our analysis suggested that also 
the major PFGE profile among Norwegian strains was similar to those previously reported.  
In Norway, 4% of invasive strains from infants were resistant to erythromycin and 
clindamycin from 2003 to 2005, but in 2006 and 2007 almost 20% of the strains were 
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resistant (Paper I and Paper II). A tendency toward lower antibiotic susceptibility of GBS has 
also been shown in Sweden over the last years [60]. The increasing resistance to erythromycin 
and clindamycin in Norway and Sweden coincides with observations in other countries 
[61;190;191;195].  
The first erythromycin-resistant strains of streptococci were reported from United 
Kingdom in 1959 [196]. Yet, resistance to erythromycin and clindamycin has not been an 
acknowledged problem until the 1990s when up to 41% of GBS isolates in USA and Canada 
were reported to be resistant [61;65].  
The ORACLE I and II trials [197;198] concluded that erythromycin given to pregnant 
women with premature rupture of the membranes (pPROM) and spontaneous preterm labour 
was associated with a range of health benefits for the neonate, and a probable reduction in 
childhood disability. This statement probably led to an increased use of erythromycin in 
maternity wards. It is not known if frequent use of erythromycin in pregnant women can 
explain the increased erythromycin resistance of GBS. However, the increasing resistance 
among GBS strains, also in Norway, indicates that erythromycin to women with penicillin 
allergy should no longer be the drug of choice in pregnant women.  
 
Molecular epidemiology 
The study on molecular characteristics of invasive strains from infants did not indicate that 
sequence types and clonal complexes were associated with specific characteristics like 
susceptibility to erythromycin and clindamycin, geographic origin, early or late onset GBS 
disease and lethality (Paper II). 
Some studies have found relatively more type III strains with sequence type (ST) 17 in 
invasive strains compared to colonising strains [199;200]. This has indicated that ST17 might 
represent a virulent clone of GBS. However, a study by Davies et al could not confirm the 
claimed association between sequence type and invasiveness [201]. In our material of 
invasive strains only, none of 23 cases with ST17 strains were fatal, none were resistant to 
erythromycin or clindamycin and they were equally distributed between early and late onset 
disease. With the possible exception of ST17, published reports suggest that GBS STs and 
clonal complexes (CCs) seem to be equally distributed in invasive and non-invasive strains 
[201-204]. Our study suggested a lack of association between ST and characteristics 
interesting to the clinician. These observations also coincide with observations of other 
species [37;205]; the clonal groups are observed at the same frequencies regardless of whether 
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the data are based on isolates from cases of invasive disease or asymptomatic carriage. In 
general, the MLST data alone do not provide information regarding the virulence potential of 
an isolate [37]. Possible explanations for this might be:  
• There are no genetic differences between isolates regarding the tendency to cause 
disease.  
• Other factors such as host susceptibility, within-host evolution and ‘opportunistic’ 
components of the bacteria are important. 
• Strains differ in virulence potential, but the genetic basis for these differences is not 
linked (i.e. is not reflected by) to the MLST data [37]. “While MLST focuses on the 
stable core genome encoding essential housekeeping functions, ‘specialist’ 
phenotypes, which include clinically relevant properties, are more often encoded on 
accessory genes or elements, which can be rapidly disseminated throughout a 
population and equally rapidly lost.”[37].  
 
These observations emphasise the question of whether MLST is a relevant method for 
surveillance of disease (virulence), intervention (antibiotic resistance) or emergence (host or 
geographical source). Correlations between MLST genotype and clinical phenotypes are 
probably not an aim for MLST, and the clinician or epidemiologist will not be provided with 
reliable information regarding an isolate. Thus, neither our study nor any other studies 
indicate that MLST is the method of choice in surveillance of GBS disease. Instead, MLST 
provides a ‘population framework’, which means that isolates with similar or identical MLST 
genotypes are closely related, having descended from a recent common ancestor. “The 
ambition of MLST is to identify what an isolate is, not what it does” [37].  
Invasive type V strains from infants in Norway, 2006 and 2007, were also analysed with 
PFGE (Paper II). Using PFGE we were to some extent able to discriminate between type V 
strains with different clinical properties as resistance to erythromycin and clindamycin, 
inducible clindamycin resistance and lethality. By visually comparing published gel images, 
similarities between a major PFGE profile of type V strains in our study and the most 
common PFGE pattern of type V strains published in the US, France and Germany could be 
inferred [191;192;194]. However, to make this comparison more accurate, it would have been 
necessary to run a new PFGE with all strains in the same gel.  
Methods used for investigating local and global epidemiology should ideally be able to 
distinguish accurately between different strains within a bacterial species and assign isolates 
which have descended from a recent common ancestor to the same molecular type. Isolates 
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that only share a more distant common ancestor should be assigned to different molecular 
types. Neither MLST nor PFGE fulfil all these criteria and the methods are also resource-
demanding. Consequently, there is a need for supplementary methods or may be even 
methods that can replace MLST and PFGE.   
 
Methods for detection of GBS in pregnant women 
The real-time PCR targeting the sip gene proved to be very sensitive and specific. The method 
can replace the culture method in detecting GBS colonisation in pregnant women at term. 
PCR assays for GBS can detect as little as one colony forming unit (CFU) per PCR 
reaction [206]. The PCR method should therefore in theory be at least as sensitive as culture. 
Still, in our study, as in many other studies [146;207;208], PCR seemed to be slightly less 
sensitive than culture (0.97) (Paper III). This might have many possible explanations. To 
make a PCR test suitable for screening for GBS colonisation in pregnant women, all steps in 
the process have to be optimised; from the collection of specimens, via DNA extraction, to the 
actual PCR reaction with optimal primers and temperatures. 
In our study, culture was favoured by receiving more test material than PCR. We 
dissolved the specimens in 550 µl Nacl and used 50 µl of this solution for culture and 300 µl 
for DNA extraction. The extracted DNA was eluated in 100 µl and only 2 µl of this eluate 
was analysed by PCR. This means that the methology favoured culture by a factor of 8.3 
compared with PCR. The sensitivity of 0.97 compared with culture must therefore be 
considered very high.  
The result of the culture is dependent on many steps in the process, the collection site, 
interval from the collection to the analysis [140], the storage, selective and enrichment media 
and proper interpretation of the bacterial colonies [144]. Thus, colonisation rates reported 
from different geographic areas and performance of alternative tests as PCR are influenced by 
the quality of the “gold standard” and might be an important bias in many studies.   
 
 
Screening strategy 
What is a QALY worth? In our study we used two different cost effectiveness thresholds or 
willingness to pay (WTP) (Paper IV). Assuming that the QALY (quality adjusted life year) is 
an adequate measure of health care outcomes, the question of what value that should be 
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placed on a QALY is not easily solved. WHO has suggested an estimate of 3 times a nation’s 
per capita gross domestic product for each disability-adjusted life year (DALY) averted. In 
cost effectiveness analyses from USA, US $50 000 per QALY is often used. A study by 
Devlin and Parkin retrospectively examined 33 health technology decisions made by The 
National Institute for Health and Clinical Excellence (NICE) [209]. The study revealed that 
NICE did not always stuck to their own range of acceptable cost effectiveness. Factors like 
uncertainty of estimates and burden of disease could explain the probability of acceptance of 
extra costs per QALY. The use of willingness to pay (WTP) to value a QALY might also be 
problematic because the public preference for an increased unit of health may differ according 
to the characteristics of the population.  It has been reported that people will pay more to 
avoid a decrease in health than to increase health [210]. The public usually gives a higher 
value to QALYs than policy-makers do and more wealthy countries put a higher value on a 
QALY than less wealthy countries.  
 
Influence of time The study on intrapartum vs. antepartum screening in Paper IV showed that 
time influenced on the feasibility of intrapartum screening. A weakness of the study might be 
that the study was performed at one single hospital with a study population of 836 pregnant 
women. The population studied, and the routines for admission of pregnant women at the 
hospital might not apply to other areas. Still, the interval between start of labour and delivery 
is very variable and also depends on whether the woman is nullipara or not, but is probably 
not dependent of race and culture [211]. There is therefore reason to believe that routines for 
admission to a maternity ward do not differ much from hospital to hospital or from country to 
country. Nevertheless, a study from USA showed a median interval between admission and 
delivery of 7.9 hours [212], compared to the 12.9 hours in our study. This suggests that the 
feasibility of intrapartum screening might be even lower in a US population.  
 
Screening of low-risk women only The rationale of comparing screening strategies in low-
risk women was based on a study of Colbourn et al. They claimed that infants of women with 
high risk for EOD would have an increased risk of non-GBS sepsis as well. Thus, IAP to all 
high-risk women would therefore be cost effective independent of GBS carrier status [97]. 
This is in contrast to previously published studies claiming that the main advantage of 
intrapartum PCR is the benefit of risk stratification on presentation for delivery and especially 
when women deliver prematurely. These conclusions have partly been based on a study by 
Schuchat et al suggesting that risk factors for EOD were unrelated to sepsis attributable to 
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other organisms [54]. They explained this by the possible different route of transmission 
between GBS and other organisms. For example, GBS is acquired from the mother in nearly 
all cases of EOD and only 7% of GBS cases presented after the first day of life. By contrast, 
39% of non-GBS cases presented after the first day of life and consequently, may represent 
infections acquired during hospitalisation or through contact with others [54]. An exception 
was prematurity which is an important risk factor for both GBS and non-GBS infections 
presenting at day one. The applicability of the risk-based approach to prevention of other 
infections will depend on the prevalence of risk conditions among these cases and on the 
effectiveness of IAP against other causes of early onset disease.  
 
Compliance with recommended strategy In 1998, recommendations for prevention of GBS 
disease in infants were introduced in Norway. But in contrast to the decrease in incidence 
observed in Australia and USA the last 10-20 years, the incidence of invasive GBS disease in 
infants in Norway has been unchanged (Paper I and Figure 5). Thus, even if the incidence is 
similar to what is observed in USA, this might indicate that there is a potential for 
improvements of preventive strategies in Norway.  
Studies from USA have suggested that the benefits of the screening strategy compared 
with the risk-factor strategy stemmed from identifying GBS colonised women who did not 
present with obstetric risk factors, and that women who were GBS positive were more likely 
to receive intrapartum antibiotics than were women with obstetric risk factors in the risk 
cohort [54;65;212]. Two studies from Norway, although based on small numbers, suggest that 
hospital staff do not comply with recommended directives for prevention of GBS disease in 
infants [188] (G. Waal and I. Engedal. Intrapartum antibiotikaprofylakse ved terminfødsler, 
fødeavdelingen St. Olavs Hospital, 2004. Student thesis, NTNU 2008). The previously 
mentioned MSIS-report on invasive GBS disease in Norway from January 2005 to July 2006 
showed that only one out of eight women with rupture of membranes more than 24 hours, and 
only two out of ten women giving birth at gestational age <33 weeks received IAP [188]. In 
addition, a retrospective study from St. Olavs Hospital showed that only 4/47 women with 
risk factors received IAP (Waal and Engedal. Student thesis, NTNU 2008). The student thesis 
also revealed that the directives in some instances were vague and made it difficult to deduce 
whether the staff had complied with the strategy or not. Also in Sweden there seem to be a 
low compliance with directives for IAP; only 14% of women with any risk factor had 
received IAP for at least two hours according to a study by Hakansson et al [67]. These 
studies indicate that even if a risk factor based strategy for prevention of invasive GBS 
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disease is recommended, only a few women with risk factors actually receive IAP. Possible 
explanations of this might be: 
• It is difficult to implement extra routines in maternity wards [213]  
• The directives for IAP are too vague  
• Medical personnel in maternity wards (at least in Norway and Sweden) are reluctant to 
accept and implement directives that include more use of antibiotics. (There is an 
ongoing discussion whether peripartum antibiotics may result in more resistance in 
non-GBS bacteria [214], and also whether antibiotics might lead to a chronic abnormal 
gut flora that may have health consequences for the infant later in life [215]).   
 
A better implementation of existing directions for IAP and more precise guidelines could 
possibly reduce the incidence of GBS disease in infants, also in Norway. 
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Main conclusions 
 
• The incidence of invasive GBS disease in infants has been stable in Norway during the 
period from 1996 to 2006, and the incidence of early onset disease is similar to what 
has been observed in other developed countries.  
• The incidence of invasive GBS disease in adults and elderly increased significantly 
from 1996 to 2006.  
• Both phenotypical and genotypical characteristics of invasive GBS strains from 
infants in Norway are comparable to characteristics of strains reported from other 
countries.  
• The Real-time PCR targeting the sip gene is suitable for detection of GBS colonisation 
in pregnant women at term. 
• Intrapartum screening of low-risk pregnant women is not cost effective compared with 
antepartum screening in week 35-37 due to shortage of time and higher costs. 
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Future aspects 
 
• Improved methods for epidemiological typing                                                                                     
The available methods for epidemiological typing of GBS are expensive, take much 
laboratory recourses and do not fulfil all criteria for local and global epidemiology. A 
low cost typing method that is rapid, reproducible, easy to perform, with the 
portability like MLST and the ability to recognise the epidemic isolates would be a 
useful tool for outbreak management and surveillance of virulence, antibiotic 
resistance and detecting sources of virulent strains. Methods like multiple-locus 
variable number tandem repeat analysis (MLVA) based on differences in the variable 
number of tandem repeats (VNTR) on multiple loci on the chromosome of bacteria 
have shown to be useful in analysis of other bacteria than GBS. MLVA might be 
useful for epidemiological typing of GBS. 
 
• More sensitive tests for neonatal GBS sepsis                                                                                      
Today many cases of invasive GBS disease are probably undetected due to blood 
culture negative sepsis in neonates. This makes surveillance of GBS disease in infants 
and evaluation of preventive strategies difficult. To improve the surveillance and 
evaluation of different preventive strategies, more sensitive diagnostic tests for 
neonatal GBS sepsis are required. 
 
• Development of a vaccine against GBS                                                                                                 
Even with improved methods to detect women at risk, intrapartum antibiotic 
prophylaxis will not eradicate early onset GBS disease and will have no effect on late 
onset GBS disease. In addition, possible negative effects of antibiotics make 
preventive strategies based on antibiotics inadvisable. A successful GBS vaccine could 
reduce mucosal bacterial colonisation, produce both humoral and mucosal immunity, 
and thereby prevent neonatal disease more effectively than the current strategies with 
intrapartum antibiotic prophylaxis. 
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